MPR Weekly Dose 99 - Oral COVID-19 candidate reduces risk of death; aromatherapy sprays recalled; Presbyopia Tx; Naloxone alternative; Migraine drug head-to-head study

<p><span style="font-weight: 400;">This week there’s positive news for the COVID-19 oral antiviral candidate, Paxlovid; The CDC expands a recall for aromatherapy sprays connected to fatal cases of a rare tropical disease; The first eye drop to treat presbyopia is approved; An alternative to naloxone gets fast tracked; And a study compares the migraine treatments erenumab and topiramate. </span></p>